Elizabeth Lihua Budde, M.D., Ph.D.

Elizabeth Budde, M.D., Ph.D. is a well-recognized clinical expert and researchers in the area of blood cancers. Her academic and clinical interests center on novel treatment for patients with lymphoma and leukemia. As a physician scientist, she leads a group of researchers in her laboratory designing and investigating the use of immunotherapy to treat blood cancers and other diseases.

She leads the Immunotherapy Modality Team and chairs the Clinical Cellular Immunotherapy Committee at the institution. She also serves as a member on several national committees including National Comprehensive Cancer Network (NCCN) guidelines for B Cell Lymphoma, NCCN guidelines for Management of Immunotherapy-related Toxicities, and Alliance of American Cancer Institute CAR T Working Group.

Dr. Budde has received many honors and awards for her work. She was chosen as a Special Fellow in Clinical Research awardee by The Leukemia & Lymphoma Society, and an awardee of the Stop Cancer Foundation seed grant in 2016. She is also a recipient of the prestigious Damon Runyon Cancer Research Foundation Clinical Investigator Award (2014-2019). She has published many peer-reviewed articles that have been featured in prominent journals including the Journal of Clinical Oncology, Blood, Clinical Cancer Research, Journal of Immunology. She has also given many invited presentations at national and international meetings on her work.

Dr. Budde holds patents for new drugs currently under development in lymphoma and leukemia. She is the principal investigator of innovative translational research protocols and maintains a dynamic portfolio of clinical trials. Dr. Budde is devoted to making promising new treatments available to all her patients.

• Ong, S. Y., Pak, S., Mei, M., Wang, Y., Popplewell, L., Baird, J. H., Herrera, A. F., Shouse, G., Nikolaenko, L., Zain, J., Godfrey, J., Htut, M., Aribi, A., Spielberger, R., Mansour, J., Forman, S. J., Palmer, J., & Budde, L. E. (2023). Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. American journal of hematology, 10.1002/ajh.27069. Advance online publication. https://doi.org/10.1002/ajh.27069
• Cao, Y., Marcucci, E. C., & Budde, L. E. (2023). Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting. Journal of hematology & oncology, 16(1), 69. https://doi.org/10.1186/s13045-023-01462-0
• Bartlett, N. L., Assouline, S., Giri, P., Schuster, S. J., Cheah, C. Y., Matasar, M., Gregory, G. P., Yoon, D. H., Shadman, M., Fay, K., Yoon, S. S., Panizo, C., Flinn, I., Johnston, A., Bosch, F., Sehn, L. H., Wei, M. C., Yin, S., To, I., Li, C. C., … Budde, L. E. (2023). Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood advances, 7(17), 4926–4935. https://doi.org/10.1182/bloodadvances.2022009260
• Ladbury, C., Dandapani, S., Hao, C., Fabros, M., Amini, A., Sampath, S., Glaser, S., Sokolov, K., Yeh, J., Baird, J. H., Kambhampati, S., Herrera, A., Mei, M., Nikolaenko, L., Shouse, G., & Budde, L. E. (2023). Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma. Cancers, 15(6), 1747. https://doi.org/10.3390/cancers15061747
• Strati, P., Coleman, M., Champion, R., Ma, S., Patti, C., Levy, M. Y., Lossos, I. S., Geethakumari, P. R., Lam, S., Calvo, R., Higgins, K., & Budde, L. E. (2022). A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. British journal of haematology, 199(1), 76–85. https://doi.org/10.1111/bjh.18368
• Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Cheah, C. Y., Wei, M. C., Yin, S., Li, C. C., Huang, H., Kwan, A., Penuel, E., & Bartlett, N. L. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. The Lancet. Oncology, 23(8), 1055–1065. https://doi.org/10.1016/S1470-2045(22)00335
• Budde, L. E., Assouline, S., Sehn, L. H., Schuster, S. J., Yoon, S. S., Yoon, D. H., Matasar, M. J., Bosch, F., Kim, W. S., Nastoupil, L. J., Flinn, I. W., Shadman, M., Diefenbach, C., O'Hear, C., Huang, H., Kwan, A., Li, C. C., Piccione, E. C., Wei, M. C., Yin, S., … Bartlett, N. L. (2022). Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(5), 481–491. https://doi.org/10.1200/JCO.21.00931
• Dulan, S. O., Viers, K. L., Wagner, J. R., Clark, M. C., Chang, B., Gorospe, G. L., Londrc, A., Brown, A. S., Rosenthal, J., Smith, E. P., Forman, S. J., Snyder, D. S., & Budde, L. E. (2020). Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(8), 1386–1393. https://doi.org/10.1016/j.bbmt.2020.03.021
• Xue, T., & Budde, L. E. (2020). Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematology/oncology clinics of North America, 34(3), 575–587. https://doi.org/10.1016/j.hoc.2020.01.006
• Budde, L. E., Wu, D., Martin, D. B., Philip, M., Shustov, A. R., Smith, S. D., Gooley, T. A., Chen, T. L., Libby, E. N., Chen, E. Y., Kojouri, K., Langerak, A., Roden, J. E., Press, O. W., & Gopal, A. K. (2018). Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. British journal of haematology, 183(4), 601–607. https://doi.org/10.1111/bjh.15585
• Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Jul 10;39(20):2257-2265. doi: 10.1200/JCO.21.00108. Epub 2021 Apr 28. PMID: 33909449.
• Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. PMID: 32135517.
• Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, Deal AM, Noe JF, Ansell SM. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv. 2020 Jun 9;4(11):2548-2555. doi: 10.1182/bloodadvances.2020001871. PMID: 32516414; PMCID: PMC7284091.
• Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang WC, Aguilar B, Brito A, Sarkissian A, Bandara NA, Yang L, Wang J, Wu X, Zhang J, Priceman SJ, Qin H, Kwak LW, Budde LE, Thomas SH, Clark MC, Popplewell L, Siddiqi T, Brown CE, Forman SJ. The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma. Cancer Immunol Res. 2020 Oct 22: canimm.0236.2020. doi: 10.1158/2326-6066.CIR-20-0236. Epub ahead of print. PMID: 33093217.
• Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15. PMID: 32667831; PMCID: PMC7499617.
• Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/31136781" CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019
• Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Publications Langerak A, Roden JE, Press OW, Gopal AK. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14. PMID: 30596402; PMCID: PMC6314205.
• Xue T, *Budde LE. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 Jun;34(3):575-587. doi: 10.1016/j.hoc.2020.01.006. Epub 2020 Mar 27. PMID: 32336421. *corresponding author
• Langerak A, Roden JE, Press OW, Gopal AK. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14. PMID: 30596402; PMCID: PMC6314205.
• Dulan SO, Viers KL, Wagner JR, Clark M, Chang B, Gorospe GL, Londrc A, Brown AS, Rosenthal J, Smith EP, Forman SJ, Snyder DA, *Budde LE. Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program Biol Blood Marrow Transplant 2020;26(8):1386-1393. *corresponding author
• Xue T, *Budde LE. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 Jun;34(3):575-587. doi: 10.1016/j.hoc.2020.01.006. Epub 2020 Mar 27. PMID: 32336421. *corresponding author
• Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Jul 10;39(20):2257-2265. doi: 10.1200/JCO.21.00108. Epub 2021 Apr 28. PMID: 33909449.
• Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang WC, Aguilar B, Brito A, Sarkissian A, Bandara NA, Yang L, Wang J, Wu X, Zhang J, Priceman SJ, Qin H, Kwak LW, Budde LE, Thomas SH, Clark MC, Popplewell L, Siddiqi T, Brown CE, Forman SJ. The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma. Cancer Immunol Res. 2020 Oct 22: canimm.0236.2020. doi: 10.1158/2326-6066.CIR-20-0236. Epub ahead of print. PMID: 33093217.
• Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15. PMID: 32667831; PMCID: PMC7499617.
• Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, Deal AM, Noe JF, Ansell SM. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv. 2020 Jun 9;4(11):2548-2555. doi: 10.1182/bloodadvances.2020001871. PMID: 32516414; PMCID: PMC7284091.
• Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. PMID: 32135517.
• Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. HYPERLINK CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019 Jun;74:52-63.